Hims & Hers is launching a tracker of GLP-1 shortages to push back against the FDA's recent moves to end compounding copycats ...

The agency is also evaluating Novo Nordisk’s (NVO) semaglutide drugs for the ... clinics have been deemed risky since they ...

While these counterfeit drugs may look legitimate, they often contain dangerous substances. "We've found things like ... The dangers to health are real. Novo Nordisk reported one counterfeit pen ...

Compounded semaglutide: Medication produced by compounded pharmacies instead of the original drug manufacturer (Novo Nordisk, ...

The analysis revealed that patients with prescriptions for GIP or GLP-1 RA drugs, e.g., Novo Nordisk A/S‘ NVO Ozempic ... role of these drugs in curbing substance-related behaviors, such ...

Just over a year ago, New Zealand customs officials started to intercept batches of injectable medications labelled Fitaro ...

A Novo Nordisk production facility in Denmark where semaglutide, the active ingredient in its weight loss and type 2 diabetes ...

Other pharmaceutical players such as Roche, Amgen, Pfizer, AstraZeneca and Boehringer also have obesity drugs in the pipeline ...

Drugs such as Novo Nordisk’s blockbuster Ozempic can cut ... “Our study… reveals the possibilities of a novel therapeutic pathway in substance use treatment," the study’s lead researcher ...

GLP-1 drugs such as Novo Nordisk’s Ozempic can cut drug and alcohol abuse by around half. Meanwhile, tech companies are ...

The case that Ozempic (NVO) and other GLP-1 medications could help people with substance ... maker Novo Nordisk and Eli Lilly (LLY), the producer of Mounjaro and Zepbound (both GLP-1 drugs for ...

There are also early indications that GLP-1s could be used to treat substance-use disorders ... to make weight-loss drugs both better and cheaper. Although Novo Nordisk and Eli Lilly are expected ...